Premium
Endothelium Specific Up Regulation of HO‐1 Gene by Lentiviral Transfection Promotes Release of Positive Regulators of Adipoctye Function
Author(s) -
Getty Morghan Schuyler,
Kim Dong Hyun,
Abraham Nadar G.
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.lb509
Subject(s) - adipogenesis , transfection , mesenchymal stem cell , paracrine signalling , microbiology and biotechnology , endothelium , adipocyte , heme oxygenase , chemistry , endothelial stem cell , biology , adipose tissue , heme , endocrinology , in vitro , biochemistry , receptor , gene , enzyme
We aimed to characterize the physiological effects of up regulating endothelial heme oxygenase‐1 (HO‐1) on adipogenesis in human mesenchymal stem cells (MSCs). Microvessel endothelial cells (HMEC‐1) were cultured along with a lentiviral (lenti) construct expressing human HO‐1 under the control of endothelium specific promoter vascular endothelium cadherin heme oxygenase (VECAD‐HO‐1) and Lenti‐VECAD‐GFP used as the control. In complementary experiments HMEC‐1 cells were cultured in the presence or absence of tin‐mesoporphrin (5 μM). Conditioned media (CM) was harvested and tested at 5%, 10% and 20%. The 10% CM from HMEC cells was used for ideal effect, along with adipogenic media, to measure paracrine effect on adipogenesis in MSCs. The MSCs exposed to CM from VECAD‐HO‐1 transfected cells demonstrated reduced (10.2 ± 1 at 490nm) adipogenesis (lipid droplets) as compared to MSCs exposed to CM from Lenti‐VECAD‐GFP cells (17.0±2, p>;0.05). CM from HMEC‐1 cells treated with inhibitor of HO‐1 activity promoted higher adipogenesis with increased adipocyte hypertrophy as opposed to HMEC‐1 treated activity transfected with the VECAD‐GFP control ( 24.5±1, p<0.01). These observations suggest that EC under stressed conditions releases a negative regulator as seen in VECAD‐HO‐1 in presence of HO‐1 inhibitor and increases adipocyte dysfunction.